The Journal of investigative dermatology最新文献_第10页

Fetal Fibroblast Heterogeneity Defines Dermal Architecture during Human Embryonic Skin Development.

The Journal of investigative dermatology Pub Date : 2025-01-27 DOI: 10.1016/j.jid.2024.12.027

Noriko Morioka, Clarisse Ganier, Fiona M Watt

{"title":"Fetal Fibroblast Heterogeneity Defines Dermal Architecture during Human Embryonic Skin Development.","authors":"Noriko Morioka, Clarisse Ganier, Fiona M Watt","doi":"10.1016/j.jid.2024.12.027","DOIUrl":"10.1016/j.jid.2024.12.027","url":null,"abstract":"To investigate the heterogeneity of fibroblasts in human fetal skin, we analyzed published single-cell RNA-sequencing data (7 and 16 weeks after conception) and performed single-molecule FISH to map their spatial distribution and predicted dynamic interactions. Clustering revealed 8 fibroblast populations with changes in developmental stage-specific abundance. Proliferative cells (MKI67+) were present at all stages. The appearance of dermal papilla (PRDM1+) and hair follicle (SLC26A7+) fibroblasts coincided with hair follicle maturation, whereas fibroblasts (apolipoprotein E positive) specifically associated with blood vessels increased in abundance as the vessels developed. HOXC5 was a marker of the most abundant fibroblasts 7-8 weeks after conception; this cluster was diminished 9-13 weeks after conception and undetectable subsequently. A second population (PLAT+) decreased in abundance with the same kinetics. Fibroblasts corresponding to papillary dermis (GRP+) were predominant 9-13 weeks after conception, whereas reticular dermal fibroblasts (ASPN+) were the major cluster 14-16 weeks after conception. Partition-based graph abstraction and pseudotime analysis indicated that the HOXC5+ fibroblasts were closely connected with the papillary and hair follicle fibroblasts, whereas the PLAT+ fibroblasts were connected with reticular and vascular fibroblasts. Dermal papilla fibroblasts were the most highly differentiated. Integration of fetal and adult datasets distinguished the adult and fetal papillary clusters from the reticular clusters.","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Demystifying Small-Molecule Phosphodiesterase-IV Inhibition: Computer-Aided Rational Drug Design for Future Precision Drug Development.

The Journal of investigative dermatology Pub Date : 2025-01-27 DOI: 10.1016/j.jid.2024.11.018

Naiem T Issa

引用次数: 0

Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic Disease. IDEOM MSK 问卷（IDEOM MSK-Q）的结构效度：测量银屑病患者肌肉骨骼症状的工具。

The Journal of investigative dermatology Pub Date : 2025-01-27 DOI: 10.1016/j.jid.2024.10.619

Lourdes M Perez-Chada, George Gondo, Carly Grant, Michael Woodbury, Alison H Kucharik, April W Armstrong, Lihi Eder, Philip Mease, Alexis Ogdie, Vibeke Strand, Alice B Gottlieb, Joseph F Merola

引用次数: 0

Internal cancers in solid organ transplant recipients with a post-transplant skin cancer: a cohort study. 伴有移植后皮肤癌的实体器官移植受者的内脏癌：一项队列研究。

The Journal of investigative dermatology Pub Date : 2025-01-24 DOI: 10.1016/j.jid.2024.11.027

Lucy J Navsaria, Yao Li, Anokhi Jambusaria, Lee E Wheless, Mackenzie R Wehner

引用次数: 0

Knockout of IL-1R1 Reduced Inflammation and Improved Survival in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa.

The Journal of investigative dermatology Pub Date : 2025-01-23 DOI: 10.1016/j.jid.2025.01.010

Morgan Anderson-Crannage, Rahim Hirani, Jian Pan, Mishel Ramirez, Meijuan Tian, Alexander Nyström, Mitchell S Cairo, Yanling Liao

引用次数: 0

Need for Trial Design Change in Epidermal Necrolysis (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis): Example of Cyclosporine.

The Journal of investigative dermatology Pub Date : 2025-01-22 DOI: 10.1016/j.jid.2024.11.020

Saskia Ingen-Housz-Oro, Nicolas de Prost, Pierre Wolkenstein

引用次数: 0

Downregulated TFPI2 Accelerates Skin Aging by Repressing the Cell Cycle through Phosphoinositide 3-Kinase/Protein Kinase B/CDC6 Pathway.

The Journal of investigative dermatology Pub Date : 2025-01-21 DOI: 10.1016/j.jid.2024.11.028

Fan Wang, Caitan Yi, Yun Zhong, Lei Zhou, Xin Meng, Rui Mao, Yi Guo, Hongfu Xie, Yiya Zhang, Yingxue Huang, Ji Li

{"title":"Downregulated TFPI2 Accelerates Skin Aging by Repressing the Cell Cycle through Phosphoinositide 3-Kinase/Protein Kinase B/CDC6 Pathway.","authors":"Fan Wang, Caitan Yi, Yun Zhong, Lei Zhou, Xin Meng, Rui Mao, Yi Guo, Hongfu Xie, Yiya Zhang, Yingxue Huang, Ji Li","doi":"10.1016/j.jid.2024.11.028","DOIUrl":"10.1016/j.jid.2024.11.028","url":null,"abstract":"TFPI2 is known to regulate the proliferation of various cell types and tumor tissues; however, its role in the process of skin aging has not been elucidated. In this study, we identified TFPI2 as a potential antagonist of aging. Our findings indicate that TFPI2 expression is downregulated in aging skin tissues and senescent human dermal fibroblasts and that the depletion of TFPI2 accelerates the senescence of human dermal fibroblasts and skin aging. RNA-sequencing analysis revealed that CDC6, a protein associated with cell cycle, is a downstream target of TFPI2. Further liquid chromatography-mass spectrometry analysis confirmed that TFPI2 interacts with p85β to activate the phosphoinositide 3-kinase/protein kinase B pathway. Subsequent experiments revealed that the activation of the phosphoinositide 3-kinase/protein kinase B pathway alleviates senescence in human dermal fibroblasts by promoting CDC6 expression and facilitating cell cycle progression. Collectively, these findings underscore the crucial role of the TFPI2/phosphoinositide 3-kinase/protein kinase B/CDC6 pathway in skin aging and highlight its potential for the development of antiaging interventions.","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.

The Journal of investigative dermatology Pub Date : 2025-01-21 DOI: 10.1016/j.jid.2024.12.025

Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, Kristin Drda, Hui Gu, Harald Vangerow, Mary Flack, Julia Korell, Howard Sofen, Kim A Papp

{"title":"Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.","authors":"Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, Kristin Drda, Hui Gu, Harald Vangerow, Mary Flack, Julia Korell, Howard Sofen, Kim A Papp","doi":"10.1016/j.jid.2024.12.025","DOIUrl":"10.1016/j.jid.2024.12.025","url":null,"abstract":"Trial design: This 2-part, double-blinded trial assessed the RORγt inhibitor BI 730357 in plaque psoriasis.Methods: In part 1, patients were randomized 2:2:2:2:1 to 25, 50, 100, and 200 mg BI 730357 or placebo once daily (fasting conditions); nonresponders were switched to higher doses. In part 2, a separate patient set was randomized 4:4:1 to receive BI 730357 (400 mg once daily, 200 mg twice daily) or a placebo (fed conditions). Patients from parts 1 and 2 could enter a long-term extension trial. Coprimary endpoints included ≥75% reduction from baseline in PASI75 and static Physician's Global Assessment score of 0/1 (clear/almost clear) at week 12.Results: In total, 274 patients were treated (178 [part 1] and 96 [part 2]). In part 1, 12 (30.0%) patients achieved PASI75 (P = .0062), and 11 (27.5%) achieved static Physician's Global Assessment of 0/1 (P = .0095) with BI 730357 200 mg versus none receiving placebo. Exposure-response relationship plateaued at ≥200 mg once daily BI 730357. Drug-related adverse events occurred in ≤15.8% of patients. Of 165 patients who entered the long-term extension, 93 (56.4%) achieved PASI75 during treatment, and ≤18.5% experienced a drug-related adverse event.Conclusions: BI 730357 was well tolerated, with moderate efficacy versus placebo in plaque reduction (clinicaltrials.gov: NCT03635099 and NCT03835481).","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subtype Specific Alterations in the Skin Microbiome of Patients with Cutaneous T-Cell Lymphoma.

The Journal of investigative dermatology Pub Date : 2025-01-21 DOI: 10.1016/j.jid.2025.01.009

Caroline Meyer Olesen, Sofie Marie Edslev, Gitte Nygaard Aasbjerg, Yasemin Topal Yüksel, Tove Agner, Maria Rørbæk Kamstrup

引用次数: 0

An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms.

The Journal of investigative dermatology Pub Date : 2025-01-21 DOI: 10.1016/j.jid.2025.01.007

Yuma Gohara, Rie Kinoshita, Nahoko Tomonobu, Fan Jiang, Yukiko Matsunaga, Yuki Hashimoto, Tomoko Honjo, Ken-Ichi Yamamoto, Hitoshi Murata, Toshiki Ochi, Ni Luh Gede Yoni Komalasari, Akira Yamauchi, Futoshi Kuribayashi, Yoshihiko Sakaguchi, Junichiro Futami, Yusuke Inoue, Eisaku Kondo, Shinichi Toyooka, Shin Morizane, Akira Ishiko, Shigeru Morita, Kazumi Sagayama, Kenichiro Nakao, Masakiyo Sakaguchi

{"title":"An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms.","authors":"Yuma Gohara, Rie Kinoshita, Nahoko Tomonobu, Fan Jiang, Yukiko Matsunaga, Yuki Hashimoto, Tomoko Honjo, Ken-Ichi Yamamoto, Hitoshi Murata, Toshiki Ochi, Ni Luh Gede Yoni Komalasari, Akira Yamauchi, Futoshi Kuribayashi, Yoshihiko Sakaguchi, Junichiro Futami, Yusuke Inoue, Eisaku Kondo, Shinichi Toyooka, Shin Morizane, Akira Ishiko, Shigeru Morita, Kazumi Sagayama, Kenichiro Nakao, Masakiyo Sakaguchi","doi":"10.1016/j.jid.2025.01.007","DOIUrl":"10.1016/j.jid.2025.01.007","url":null,"abstract":"Contact hypersensitivity and atopic dermatitis are pervasive inflammatory skin diseases with similar symptoms, and their global prevalence is steadily increasing. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of contact hypersensitivity and atopic dermatitis. However, these molecules are sometimes ineffective or lose their potency during the therapeutic course. Therefore, innovative medicines are still needed for the treatment of intractable cases. We focused on S100A8/A9, a heterodimer complex of S100A8 and S100A9 that is abundant in the extracellular milieu of inflammatory skin lesions. Although S100A8/A9 is primarily recognized as a diagnostic marker protein, we have previously shown that it also plays a crucial role in contact hypersensitivity and atopic dermatitis progression. This insight inspired us to develop its inhibitory antibody, leading to the ground-breaking Ab45. In this study, we demonstrated that Ab45 effectively prevented disease symptoms in various models and that its disease-ameliorating activity likely involved the downregulation of several disease-relevant molecules, including Il-23a, Il-36g, S100a8, and S100a9. We also created a humanized version of Ab45, HuAb45, which exhibited similar effectiveness. These antibodies show great promise for the treatment of contact hypersensitivity and atopic dermatitis and possibly for other inflammatory skin diseases.","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0